Revenue
Search documents
Five9 Non-GAAP EPS of $0.78 beats by $0.05, revenue of $285.8M beats by $0.67M (NASDAQ:FIVN)
Seeking Alpha· 2025-11-06 21:35
Group 1 - The article does not provide any specific content related to a company or industry [1]
X @aixbt
aixbt· 2025-11-06 21:21
arbitrum revenue dropped 87% post-dencun. $65m quarterly to $8.2m. blob space turned their 80% margins into 15%. $5b fdv pricing in $300m annual revenue that's actually $32m. base processes more transactions and keeps the profits through coinbase integration. arb can't compete with free execution when they need $12m just to run the sequencer. ...
Why DoorDash's Stock Is Down 15% Today
Investopedia· 2025-11-06 17:35
Core Insights - DoorDash (DASH) shares fell nearly 15% after missing profit estimates and providing a weak outlook, making it the worst-performing stock in the S&P 500 on that day [1] Financial Performance - The company reported third-quarter earnings per share of $0.55, significantly below analyst expectations [2] - Revenue increased by 27% year-over-year to $3.45 billion, surpassing forecasts [2] - Orders rose by 21% to 766 million, while marketplace gross order value grew by 25% to $25 billion [2] - Costs and expenses surged by 23% to $3.19 billion due to investments in expansion and new initiatives like delivery robots [2] Future Outlook - DoorDash anticipates spending "several hundred million dollars" more in 2026 compared to 2025, indicating a commitment to growth despite rising costs [3] - The company projects adjusted EBITDA for the current quarter to be between $710 million and $810 million, which is below analyst consensus [4] - Analysts from Deutsche Bank and Oppenheimer maintained "buy" ratings but reduced their price targets to $298 and $280, respectively, due to increased costs [4] Stock Performance - Despite the recent decline, DoorDash shares have gained over 20% in value in 2025 [5]
VYNE Therapeutics GAAP EPS of -$0.17 misses by $0.04, revenue of $0.2M beats by $0.1M (NASDAQ:VYNE)
Seeking Alpha· 2025-11-06 17:05
Group 1 - The article does not provide any relevant content regarding company or industry insights [1]
Collegium Pharmaceutical Non-GAAP EPS of $2.25 beats by $0.39, revenue of $209.4M beats by $20.28M (NASDAQ:COLL)
Seeking Alpha· 2025-11-06 12:34
Group 1 - The article does not provide any specific content or key points related to a company or industry [1]
Microchip Technology Incorporated's Upcoming Earnings: A Deep Dive
Financial Modeling Prep· 2025-11-06 11:00
Core Insights - Microchip Technology Incorporated is a significant player in the semiconductor industry, focusing on microcontroller, mixed-signal, analog, and Flash-IP solutions [1] - The company is set to release its quarterly earnings on November 6, 2025, with analysts closely monitoring its performance metrics [1] Earnings Projections - Wall Street analysts project an earnings per share (EPS) of $0.33, representing a year-over-year decline of 28.3% [2][6] - The company has guided for EPS to range between $0.34 and $0.37, indicating potential variance from analyst expectations [2] Revenue Expectations - Revenue projections for the quarter are approximately $1.13 billion, reflecting a 2.7% year-over-year decline [3][6] - Microchip anticipates net sales to range between $1.11 billion and $1.15 billion, suggesting a sequential growth of 5.1% [3] Growth Drivers - The anticipated growth is driven by improving inventory levels, increased direct shipments, and strong design wins in sectors such as industrial, aerospace, and AI [3] Financial Metrics - The price-to-sales ratio is about 7.75, indicating investors are willing to pay $7.75 for every dollar of sales [4] - The enterprise value to sales ratio stands at approximately 8.91, reflecting the company's valuation in relation to its sales [4] - The debt-to-equity ratio is about 0.80, suggesting a balanced approach to leveraging debt for growth [5] - The current ratio of approximately 2.31 indicates a strong ability to cover short-term liabilities with short-term assets [5]
Wynn Resorts (NASDAQ:WYNN) Earnings Preview: Key Insights
Financial Modeling Prep· 2025-11-06 05:00
Core Viewpoint - Wynn Resorts is a significant player in the luxury casino and resort industry, with operations in Las Vegas and Macau, and is facing competition from major operators like Las Vegas Sands and MGM Resorts [1] Financial Performance - Wynn is set to release its quarterly earnings on November 6, 2025, with an estimated earnings per share (EPS) of $1.09, reflecting a 21.1% increase from the 90 cents reported in the same quarter last year [2][6] - Projected revenue for the quarter is approximately $1.77 billion, indicating a 4.3% increase from the previous year's quarter, driven by strong gaming volumes in Macau [3][6] Market Expectations - The Zacks Consensus Estimate aligns with the EPS projection, indicating market anticipation of improved financial performance [2] - Over the past four quarters, Wynn has exceeded the Zacks Consensus Estimate once and missed it three times, with an average surprise of 11.5%, suggesting potential for both positive surprises and risks of underperformance [4] Financial Metrics - Wynn's price-to-earnings (P/E) ratio is approximately 33.75, and the price-to-sales ratio is about 1.87, reflecting the market's valuation of the company relative to its earnings and revenue [5][6] - The enterprise value to sales ratio is roughly 3.33, and the enterprise value to operating cash flow ratio is approximately 17.89, providing further insight into the company's financial standing [5]
Northern Oil and Gas, Inc. (NYSE: NOG) Earnings Preview: A Look at Upcoming Q3 Results
Financial Modeling Prep· 2025-11-06 04:00
Core Viewpoint - Northern Oil and Gas, Inc. (NOG) is a significant entity in the U.S. oil and gas sector, recognized for its strategic acquisitions and operational efficiency, with upcoming earnings expected to be closely monitored by the market [1] Financial Performance - In the most recent quarter, NOG reported earnings of $1.37 per share, surpassing the Zacks Consensus Estimate of $0.87 per share, indicating a strong performance trend [2] - Previous quarter earnings were also robust, with $1.33 per share against an anticipated $1.12, showcasing NOG's ability to exceed market expectations [2] - Analysts predict a decline in earnings for the quarter ending September 2025, primarily due to lower revenues [2] Valuation Metrics - NOG's financial metrics indicate a strong position, with a price-to-earnings (P/E) ratio of approximately 3.3, suggesting a low valuation relative to earnings [3] - The company's price-to-sales ratio is about 0.9, and the enterprise value to sales ratio is approximately 1.95, reflecting favorable valuation metrics [3] - An earnings yield of around 30.3% indicates substantial return potential relative to share price [3] - The debt-to-equity ratio stands at 0.98, and the current ratio is approximately 1.21, demonstrating a balanced approach to leveraging debt and maintaining liquidity [3] Future Outlook - The upcoming earnings report and management discussion will be critical for assessing the sustainability of price changes and future earnings projections for NOG [4] - Investors and analysts are eager to determine if NOG can maintain its trend of exceeding expectations or if the anticipated earnings decline will occur [4]
Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop
ZACKS· 2025-11-05 18:21
Core Insights - Zimmer Biomet Holdings, Inc. (ZBH) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.90, exceeding the Zacks Consensus Estimate by 1.06% and reflecting a year-over-year increase of 9.2% [1][9] - The company's net sales for the third quarter reached $2.00 billion, marking a 9.7% increase year over year, but fell short of the Zacks Consensus Estimate by 0.4% [3][9] - Following the earnings announcement, ZBH's shares declined by 8.1% in pre-market trading [2] Revenue Performance - U.S. sales totaled $1.16 billion, up 10.6% year over year, while international sales reached $837.3 million, reflecting an 8.5% increase year over year [4] - Revenue growth in the Knees segment was 5.3% year over year at constant exchange rates (CER) to $792.4 million, while the Hips segment grew 3.8% to $506.2 million [5] - The S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) unit saw a significant revenue increase of 18.2% year over year at CER to $541.5 million [6] Margin and Expense Analysis - Adjusted gross margin expanded by 158 basis points year over year to 72.1%, while selling, general, and administrative expenses rose by 14.3% to $811.4 million [7] - Research and development expenses increased by 3.9% to $115.9 million, and adjusted operating margin improved by 27 basis points to 25.7% [7] Cash Position - At the end of the third quarter, ZBH had cash and cash equivalents of $1.29 billion, a significant increase from $525.5 million at the end of the second quarter [10] - Cumulative net cash provided by operating activities was $1.18 billion, compared to $993.1 million in the same period last year [10] Updated Financial Guidance - ZBH reiterated its reported revenue growth guidance for 2025 in the range of 6.7% to 7.7%, but narrowed the upper limit of its constant currency revenue growth outlook to 6.2% - 6.7% [11] - The adjusted EPS guidance for the full year remains in the range of $8.10 to $8.30, while the Zacks Consensus Estimate for adjusted EPS is $7.95 [11] Market Reaction and Outlook - Despite the adjusted EPS beating expectations and margin expansion, the overall performance disappointed investors, as indicated by the share price decline [12] - The company’s performance in key categories like Knees and Hips was softer than expected, leading to a more cautious outlook on demand [12]
USA Compression (USAC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-11-05 17:31
Core Insights - USA Compression Partners (USAC) reported a revenue of $250.26 million for the quarter ended September 2025, reflecting a 4.3% increase year-over-year [1] - The earnings per share (EPS) for the quarter was $0.26, up from $0.13 in the same quarter last year, indicating significant growth [1] - The reported revenue exceeded the Zacks Consensus Estimate of $247.33 million by 1.19%, while the EPS surpassed the consensus estimate of $0.22 by 18.18% [1] Financial Performance - Revenue-generating horsepower at period end was 3.56 billion, matching the average estimate from two analysts [4] - The average revenue-generating horsepower was reported at 3.55 billion, slightly below the two-analyst average estimate of 3.59 billion [4] - Parts and service revenues were $5.37 million, which fell short of the estimated $7.03 million by two analysts, representing a 6.7% decline compared to the year-ago quarter [4] Stock Performance - Over the past month, shares of USA Compression have returned -7.7%, contrasting with the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance against the broader market in the near term [3]